NASDAQ:CRVS

Analysts Viewpoint

CRVS stock rated an Overweight by Barclays

Daniel Torres

In a filing, Corvus Pharmaceuticals Inc revealed its Director ORBIMED ADVISORS LLC unloaded Company’s shares for reported $4.89 million on ...

Stock Earnings

Barclays’s latest rating for CRVS stock

Daniel Torres

Corvus Pharmaceuticals Inc’s filing revealed that its Director ORBIMED ADVISORS LLC unloaded Company’s shares for reported $4.89 million on Jun ...

News

Corvus Pharmaceuticals Inc (CRVS) rating initates by Barclays

Daniel Torres

Corvus Pharmaceuticals Inc’s recently made public that its Director ORBIMED ADVISORS LLC unloaded Company’s shares for reported $4.89 million on ...

Analysts Viewpoint

Corvus Pharmaceuticals Inc [CRVS] Stock sold by Insider ORBIMED ADVISORS LLC for $4.89 million

Daniel Torres

Corvus Pharmaceuticals Inc’s filing revealed that its Director ORBIMED ADVISORS LLC unloaded Company’s shares for reported $4.89 million on Jun ...

Knox Daily
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.